branebrutinib

Branebrutinib is a potent, highly selective, oral small-molecule covalent inhibitor of Bruton's tyrosine kinase (BTK). It acts by irreversibly binding to BTK and inactivating its function, leading to rapid and sustained BTK occupancy. Branebrutinib has demonstrated efficacy in preclinical models of autoimmune diseases such as lupus nephritis and is being investigated for the treatment of several immune-mediated disorders including atopic dermatitis, rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. Additionally, it has shown the ability to reverse P-glycoprotein (P-gp)-mediated multidrug resistance in cancer cells by inhibiting drug efflux activity. The drug was developed by Bristol Myers Squibb and has reached phase II clinical trials across multiple indications[1][4][5][6][7].

Other names

1912445-55-6(S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide7LBRZUYSHU